Krebs Biochemicals Valuation Multiples

Krebs Biochemicals is valued at $13M as of November 2026, a 14.7x revenue multiple. In the last fiscal year, Krebs Biochemicals revenue was $3M and Krebs Biochemicals EBITDA was ($383K).

Krebs Biochemicals Overview

About Krebs Biochemicals

Krebs Biochemicals & Industries Ltd is a biochemical company in India. It is engaged in the business of manufacture of active pharmaceutical ingredients. It has two manufacturing plants in Andhra Pradesh, India - one in Nellore and one in Vizag both Units are equipped for chemical synthesis, fermentation, and enzymatic technologies providing Krebs with production capacity.


Founded

1991

HQ

India

Employees

202

Financials (Last FY)

Revenue: $3M
EBITDA: ($383K)

EV

$37M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Krebs Biochemicals Financials

Krebs Biochemicals reported last fiscal year revenue of $3M and negative EBITDA of ($383K).

In the same fiscal year, Krebs Biochemicals generated $1M in gross profit, ($383K) in EBITDA losses, and had net loss of ($2M).


Krebs Biochemicals P&L

In the most recent fiscal year, Krebs Biochemicals reported revenue of $3M and EBITDA of ($383K).

Krebs Biochemicals is unprofitable as of last fiscal year, with gross margin of 56%, EBITDA margin of (15%), and net margin of (71%).

See analyst estimates for Krebs Biochemicals
Last FY202620272028
Revenue$3M
Gross Profit$1M
Gross Margin56%
EBITDA($383K)
EBITDA Margin(15%)
EBIT Margin(33%)
Net Profit($2M)
Net Margin(71%)
Net Debt$24M

Financial data powered by Morningstar, Inc.

Krebs Biochemicals Stock Performance

Krebs Biochemicals has current market cap of $13M, and enterprise value of $37M.

Market Cap Evolution


Krebs Biochemicals' stock price is $0.61.

Krebs Biochemicals has an EPS (earnings per share) of $-0.08.

See more trading valuation data for Krebs Biochemicals
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$37M$13M-2.1%---$-0.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Krebs Biochemicals Valuation Multiples

Krebs Biochemicals trades at 14.7x EV/Revenue multiple, and (97.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Krebs Biochemicals

Krebs Biochemicals Financial Valuation Multiples

As of November 20, 2026, Krebs Biochemicals has market cap of $13M and EV of $37M.

Krebs Biochemicals has a P/E ratio of (7.2x).

Last FY202620272028
EV/Revenue14.7x
EV/EBITDA(97.8x)
EV/EBIT(44.2x)
EV/Gross Profit26.1x
P/E(7.2x)
EV/FCF(28.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Krebs Biochemicals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Krebs Biochemicals Margins & Growth Rates

In the most recent fiscal year, Krebs Biochemicals reported gross margin of 56%, EBITDA margin of (15%), and net margin of (71%).

See estimated margins and future growth rates for Krebs Biochemicals

Krebs Biochemicals Margins

Last FY202720282029
Gross Margin56%
EBITDA Margin(15%)
EBIT Margin(33%)
Net Margin(71%)
FCF Margin(51%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Krebs Biochemicals Operational KPIs

Krebs Biochemicals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.

Access forward-looking KPIs for Krebs Biochemicals
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$0.0M
G&A Expenses to Revenue0%
Opex to Revenue90%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Krebs Biochemicals Competitors

Krebs Biochemicals competitors include Bolt Biotherapeutics, Pharma Equity Group, Celyad Oncology, Biophytis, Fractyl Health, Citius Pharmaceuticals, Actuate Therapeutics, Seres Therapeutics, BioStem Technologies and Pluri.

Most Krebs Biochemicals public comparables operate across Chemicals, Biopharmaceuticals and BioTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Bolt Biotherapeutics$8M($35M)2.5x11.3x(0.6x)-
Pharma Equity Group-($3M)--(4.2x)-
Celyad Oncology$23K($1M)568.3x-(9.7x)-
Biophytis-($10M)-99.4x(1.9x)(0.8x)
Fractyl Health-($141M)--(0.3x)(0.6x)
Citius Pharmaceuticals-($38M)-1.1x(0.3x)-
Actuate Therapeutics-($22M)--(0.5x)-
Seres Therapeutics$789K($62M)40.3x4.4x(0.5x)-

This data is available for Pro users. Sign up to see all Krebs Biochemicals competitors and their valuation data.

Start Free Trial

Krebs Biochemicals VC Funding History

Before going public, Krebs Biochemicals raised funding across 1 round.

Last private valuation of Krebs Biochemicals was $8M, after raising a round in February 2015 from Ipca Laboratories.


Krebs Biochemicals Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Feb-15SecondaryIpca Laboratories-$8MIpca Laboratories bought an 18.92% stake in Krebs Biochemicals and Industries from its promoters through an off-market transaction in February 2015 for Rs 9.54 crore. It also subscribed to a preferential allotment of Rs 12.4 crore to lift its holding to about 30% on a diluted basis, and launched an open offer at Rs 54 a share, a discount of more than 27% to the market price. Ipca could spend up to Rs 19.3 crore on the open offer, which was revised and completed on 24 November 2015 with Ipca reporting an acquisition of 37.56%. Ranbaxy, then controlled by Daiichi Sankyo, owned 11% of Krebs at the time. Krebs reported a net loss of Rs 1.4 crore on zero revenue for the quarter ended December 2014. Krebs Biochemicals is a listed Indian biotechnology company. Ipca is a Mumbai-based maker of active pharmaceutical ingredients and finished dosage forms.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Krebs Biochemicals

When was Krebs Biochemicals founded?Krebs Biochemicals was founded in 1991.
Where is Krebs Biochemicals headquartered?Krebs Biochemicals is headquartered in India.
How many employees does Krebs Biochemicals have?As of today, Krebs Biochemicals has over 202 employees.
Is Krebs Biochemicals publicly listed?Yes, Krebs Biochemicals is a public company listed on Bombay Stock Exchange.
What is the stock symbol of Krebs Biochemicals?Krebs Biochemicals trades under 524518 ticker.
When did Krebs Biochemicals go public?Krebs Biochemicals went public in 1996.
Who are competitors of Krebs Biochemicals?Krebs Biochemicals main competitors include Bolt Biotherapeutics, Pharma Equity Group, Celyad Oncology, Biophytis, Fractyl Health, Citius Pharmaceuticals, Actuate Therapeutics, Seres Therapeutics, BioStem Technologies, Pluri.
What is the current market cap of Krebs Biochemicals?Krebs Biochemicals' current market cap is $13M.
What is the current revenue of Krebs Biochemicals?Krebs Biochemicals' last fiscal year revenue is $3M.
What is the current EV/Revenue multiple of Krebs Biochemicals?Current revenue multiple of Krebs Biochemicals is 14.7x.
Is Krebs Biochemicals profitable?No, Krebs Biochemicals is not profitable.
How many companies Krebs Biochemicals has acquired to date?Krebs Biochemicals hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Krebs Biochemicals has invested to date?Krebs Biochemicals hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Krebs Biochemicals

Lists including Krebs Biochemicals

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial